Nav: Home

Experimental drug, implanted in eye, could fight glaucoma

October 14, 2016

Clarksburg, MD - An experimental drug, consisting of cells manufactured and implanted in the eye to stimulate optic nerve growth and activity, could be an entirely new way of fighting glaucoma, according to BrightFocus Foundation.

BrightFocus is helping fund a recently launched, Phase 2 [or mid-level] clinical trial designed to test the new treatment. The trial will be led by Jeffrey Goldberg, MD, PhD, chair of ophthalmology and director of the Byers Eye Institute at Stanford University. BrightFocus had previously funded Phase 1 of this trial.

"BrightFocus is proud to invest in research that may translate scientific discoveries into a new treatment for glaucoma," said BrightFocus President and CEO Stacy Haller. "We applaud Dr. Goldberg for his bold, innovative ideas and his dedication to improving sight for millions around the world."

Labeled NT-501 encapsulated cell therapy (or NT-501 ECT), the experimental glaucoma treatment consists of a capsule filled with human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF), which promotes nerve growth and activity. The capsule, implanted into the eye, releases a steady stream of those growth factors to protect the optic nerve. Subjects will be followed for two years to see if there is any change in vision.

Glaucoma, which progressively damages central version, is the number one cause of irreversible vision loss in the world. In the past, glaucoma research and treatments tended to focus on the damage caused by increased pressure inside the eye (intraocular pressure or IOP). In the innovative NT-501 ECT treatment, developed by Neurotech, the focus is on CNTF growth factors that may help the eyes' retinal ganglion cells (RGCs)--which are part of the optic nerve and carry light signals to the brain--resist damage.

Dr. Goldberg said his hypothesis is that NT-501 ECT might stop further loss of RGCs and vision (neuroprotection) or may improve existing vision (neuroenhancement), or possibly both. "It will be an enormous step forward if either of these can be demonstrated," Goldberg said. "We have no approved treatments that address the degeneration of the RGCs or their axons, so this is a huge unmet need."

The treatment has been previously tested in age-related macular degeneration and in an inherited form of macular degeneration known as retinitis pigmentosa, with no serious adverse effects to date. Being able to deliver growth factors, "directly to the eye, without significant exposure to the rest of the body, is a significant advantage of the NT-501 implant approach," Goldberg said.
-end-
For more information on this research and the clinical trial, visit http://www.brightfocus.org/ExperimentalDrug

For an interview with Dr. Goldberg, see http://www.brightfocus.org/GoldbergQA

BrightFocus Foundation funds research and promotes awareness to end glaucoma, Alzheimer's disease, and macular degeneration. The nonprofit currently manages a portfolio of more than 150 projects worldwide. For more information, visit http://www.brightfocus.org.

Contact Information

Michael Buckley, Vice President of Public Affairs
Phone: (301) 556-9370; Email: mbuckley@brightfocus.org

Alice L. Kirkman, Communications and Marketing Manager
Phone: (301) 556-9349; Email: akirkman@brightfocus.org

BrightFocus Foundation

Related Glaucoma Articles:

Long-term statin use associated with lower glaucoma risk
A new study brings the connection between statin use and risk of glaucoma into sharper focus.
Health burden of glaucoma has risen worldwide
The health burden of glaucoma has continuously increased around the globe in the past 25 years, according to an Acta Opthalmologica study.
UAlberta scientists first to pinpoint a cause of pigmentary glaucoma
An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition.
Using EHR-linked medication reminders for glaucoma patients
Mobile device reminders have been associated with better medication adherence and linking reminders to patient electronic health records (EHRs) could potentially allow some oversight by clinicians.
Traditional glaucoma test can miss severity of disease
The most common test for glaucoma can underestimate the severity of the condition by not detecting the presence of central vision loss, also known as macular degeneration, according to a new Columbia University study.
More Glaucoma News and Glaucoma Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...